Alumis (NASDAQ:ALMS) Posts Quarterly Earnings Results, Misses Estimates By $0.35 EPS

Alumis (NASDAQ:ALMS) announced its quarterly earnings data on Wednesday. The company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($0.35), Zacks reports.

Alumis Stock Performance

Shares of Alumis stock opened at $4.51 on Thursday. The firm has a fifty day simple moving average of $5.42 and a 200-day simple moving average of $7.07. Alumis has a 1-year low of $3.18 and a 1-year high of $13.53.

Wall Street Analysts Forecast Growth

ALMS has been the topic of several recent research reports. Oppenheimer initiated coverage on shares of Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Alumis in a research note on Wednesday, April 30th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $25.86.

Insider Transactions at Alumis

In related news, Director Srinivas Akkaraju bought 160,370 shares of the company’s stock in a transaction that occurred on Monday, May 5th. The shares were acquired at an average price of $4.67 per share, with a total value of $748,927.90. Following the completion of the transaction, the director now owns 3,586,788 shares of the company’s stock, valued at $16,750,299.96. The trade was a 4.68% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Martin Babler bought 15,650 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The shares were bought at an average cost of $6.44 per share, for a total transaction of $100,786.00. Following the transaction, the chief executive officer now directly owns 106,454 shares of the company’s stock, valued at $685,563.76. This trade represents a 17.23% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders bought 397,044 shares of company stock worth $1,891,895.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.